DexCom, Inc. (DXCM) Return on Assets (ROA): 13.19%
Is DexCom, Inc.’s return on assets (ROA) high or low?
DexCom, Inc.'s return on assets (ROA) of 13.19% is 49% above its 5-year average of 8.83%, near the high end of its 5-year range (4.40%–13.19%).
The return on assets (ROA) for DexCom, Inc. (DXCM) is 13.19% as of Tuesday, June 9, 2026. It is above its 12-month average by 19.47% (11.04%).
DXCM Return on Assets (ROA) Chart
DXCM Average Return on Assets (ROA) Chart
DXCM Current vs Average Return on Assets (ROA) Chart
DXCM Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
13.19%
RETURN ON ASSETS (ROA) AVG TTM
11.04%
RETURN ON ASSETS (ROA) AVG 3Y
9.26%
RETURN ON ASSETS (ROA) AVG 5Y
8.83%
RETURN ON ASSETS (ROA) AVG 10Y
0.82%
RETURN ON ASSETS (ROA) AVG 15Y
-11.72%
RETURN ON ASSETS (ROA) AVG 20Y
-29.13%
CURRENT VS TTM AVG
+19.47%
CURRENT VS 3Y AVG
+42.40%
CURRENT VS 5Y AVG
+49.46%
CURRENT VS 10Y AVG
+1517.50%
CURRENT VS 15Y AVG
+212.52%
CURRENT VS 20Y AVG
+145.28%
DXCM Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | — | 13.19% | 11.04% | 9.26% | 8.83% |
| Biogen Inc. (BIIB) | $29.39B | 4.39% | 5.11% | 6.74% | 8.29% |
| IQVIA Holdings Inc. (IQV) | $31.09B | 4.54% | 4.82% | 4.76% | 4.01% |
| Centene Corporation (CNC) | $32.69B | -8.59% | -2.29% | 0.04% | 0.75% |
| Veeva Systems Inc. (VEEV) | $27.37B | 10.12% | 9.93% | 9.72% | 10.43% |
| Zoetis Inc. (ZTS) | $34.46B | 17.28% | 17.37% | 16.33% | 15.33% |
| Waters Corporation (WAT) | $24.19B | 12.66% | 13.34% | 15.53% | 17.15% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 23.41% | 25.02% | 24.63% | 23.85% |
| Agilent Technologies, Inc. (A) | $38.26B | 10.24% | 10.56% | 11.14% | 10.55% |
| BioNTech SE (BNTX) | $21.87B | -4.96% | -3.96% | 9.16% | 17.06% |
Asset Efficiency
ROA
13.2%
ROE
30.5%
DexCom, Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for DexCom, Inc. (DXCM)?
- The return on assets (ROA) for DXCM stock is 13.19%.
- Is DexCom, Inc.'s return on assets (ROA) high or low?
- DexCom, Inc.'s return on assets (ROA) of 13.19% is 49% above its 5-year average of 8.83%, near the high end of its 5-year range (4.40%–13.19%).
- What is the TTM average return on assets (ROA) for DexCom, Inc. (DXCM)?
- The TTM average return on assets (ROA) for DXCM stock is 11.04%.
- What is the 3Y average return on assets (ROA) for DexCom, Inc. (DXCM)?
- The 3Y average return on assets (ROA) for DXCM stock is 9.26%.
- What is the 5Y average return on assets (ROA) for DexCom, Inc. (DXCM)?
- The 5Y average return on assets (ROA) for DXCM stock is 8.83%.
- What is the 10Y average return on assets (ROA) for DexCom, Inc. (DXCM)?
- The 10Y average return on assets (ROA) for DXCM stock is 0.82%.
- What is the 15Y average return on assets (ROA) for DexCom, Inc. (DXCM)?
- The 15Y average return on assets (ROA) for DXCM stock is -11.72%.
- What is the 20Y average return on assets (ROA) for DexCom, Inc. (DXCM)?
- The 20Y average return on assets (ROA) for DXCM stock is -29.13%.
DexCom, Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 13.19% |
| 2024-12-31 | 8.89% |
| 2023-12-31 | 8.64% |
| 2022-12-31 | 6.33% |
| 2021-12-31 | 4.40% |
| 2020-12-31 | 11.50% |
| 2019-12-31 | 4.22% |
| 2018-12-31 | -6.63% |
| 2017-12-31 | -5.55% |
| 2016-12-31 | -16.29% |
| 2015-12-31 | -19.73% |
| 2014-12-31 | -12.13% |
| 2013-12-31 | -24.33% |
| 2012-12-31 | -51.42% |
| 2011-12-31 | -37.14% |
| 2010-12-31 | -71.50% |
| 2009-12-31 | -114.01% |
| 2008-12-31 | -124.38% |
| 2007-12-31 | -59.38% |
| 2006-12-31 | -72.19% |
| 2005-12-31 | -54.24% |
| 2004-12-31 | -47.51% |
| 2003-12-31 | -47.74% |
| 2002-12-31 | 0.00% |
| 2001-12-31 | -72.60% |
| 2000-12-31 | -27.61% |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach